Genzyme — Proxy Contest (May 2010)
62 slides from Genzyme's proxy contest presentation, May 7, 2010
Slide 1: May 7, 2010 Investor Presentation
May 7, 2010 Investor Presentation
Slide 2: Important Information
Important Information On April 26, 2010, Genzyme filed a definitive proxy statement with the SEC in connection with the company’s 2010 annual meeting of shareholders. Genzyme shareholders are strongly advised to read carefully the company's definitive proxy statement before making any voting or inve
Slide 3: A History of Leadership in Biotechnology
A History of Leadership in Biotechnology Founded in 1981, Genzyme has grown into the fourth largest biotechnology company globally Pioneered the orphan disease drug market One of the highest revenue growth rates in the industry Consistent recognition of industry leadership National Medal of Technolo
Slide 4: Agenda
Agenda Plan for shareholder value creation Genzyme’s board and leadership Icahn’s proxy fight Concluding remarks
Slide 5: Shareholder Value Creation Action Plan
Shareholder Value Creation Action Plan Capitalize on Near-term Opportunities 2 Balance Growth with CFROI 3 Improve Operating Margins 4 5 Myozyme, Synvisc-One, and Mozobil are early in launch Alemtuzumab, Mipomersen, and Eliglustat approvals by YE:13E Optimize business mix: disposition of non-core bu
Slide 6: Our Approach to Value Creation
Our Approach to Value Creation Important Therapies Find novel therapies that set new standards of care 12 market leading products 22 Phase 3 trials underway; 19 Phase 2 trials underway Global Access Unique capabilities from registration to patient and reimbursement support 26 US and 542 global appro
Slide 7: The Result: Market Leading Products
THE RESULT: 12 Market Leading Products Delivering high value products #1 1
Slide 8: The Result: Sustainable Financial Performance
THE RESULT: Sustainable Financial Performance ($ in millions) (1) Excluding charges for major acquisitions and FAS 123R. Revenues Non-GAAP EPS(1) 23% CAGR 16% CAGR 1 $4,516 $4,605 $3,814 $3,187 $2,735 $2,201 $1,575 $1,080 2002 2003 2004 2005 2006 2007 2008 2009 $2.27 $1.95 $2.60 $2.00 $1.74 $1.47 $1
Slide 9: Balanced Product Life Cycle Will Drive Future Growth
Late-stage Development Growth Mature Launch Balanced Product Life Cycle Will Drive Future Growth Cerezyme Renagel Fludara Hectorol Synvisc-One Mozobil Renvela Myozyme Fabrazyme Aldurazyme Thyrogen Thymoglobulin Seprafilm Synvisc Campath Leukine Clolar Alemtuzumab – MS Mipomersen Lumizyme Eliglustat
Slide 10: Genzyme Took Swift Action to Fix Manufacturing Problems at Allston
Genzyme Took Swift Action to Fix Manufacturing Problems at Allston Hired best-in-class senior leadership with fresh perspectives Replaced site management Increased involvement with Quantic, a leading quality advisory firm >30 members are embedded within operations Audit of all manufacturing operatio
Slide 11: The Actions Are Already Having an Impact
The Actions Are Already Having an Impact Restored manufacturing operations in July 2009 Completed 2 production runs for each product virus-free Began re-supplying Cerezyme and Fabrazyme in late 2009 >85% of Gaucher patients returned to Cerezyme treatment ~85% of Fabry patients maintained on Fabrazym
Slide 12: Shareholder Value Creation Action Plan
Shareholder Value Creation Action Plan Capitalize on Near-term Opportunities 2 Balance Growth with CFROI 3 Improve Operating Margins 4 5 Myozyme, Synvisc-One, and Mozobil are early in launch Alemtuzumab, Mipomersen, and Eliglustat approvals by YE:13E Optimize business mix: disposition of non-core bu
Slide 13: Maximizing the Near-term Product Opportunities
First in class therapy for Pompe disease with >$1B potential Approved in over 40 countries globally Opportunity: US FDA action date (PDUFA) on Lumizyme is June 17 Only single injection product approved in the US for osteoarthritic knee pain Market leading viscosupplement with >55% share Opportunity:
Slide 14: Three Product Launches Expected by YE:2013
Three Product Launches Expected by YE:2013 Novel therapy for patients with uncontrolled LDL on maximally tolerated lipid lowering therapy Primary endpoint achieved in 2 Phase 3 trials; additional Phase 3 data expected in mid-10 Outcome studies will balance the investment with the opportunity to maxi
Slide 15: A Closer Look at Alemtuzumab: Strong 3-Year Results Published in the NEJM
Alemtuzumab vs. Interferon Beta-1a in Early Multiple Sclerosis N Engl J Med 359:1786, October 23, 2008 Original Article A CLOSER LOOK AT ALEMTUZUMAB: Strong 3-Year Results Published in the NEJM 2
Slide 16: A Closer Look at Alemtuzumab: Setting a New Standard of Efficacy in MS
A CLOSER LOOK AT ALEMTUZUMAB: Setting a New Standard of Efficacy in MS CITI, Jan 2009 Oral MS therapies Reduction in rates of relapse Reduction in relapse rate of MS disease modifying agents vs. placebo* Source: Company reports. CIR analysis. 2 * Note: alemtuzumab data is versus Rebif; all others ar
Slide 17: A Closer Look at Alemtuzumab: Positioning as The New Standard of Care
16 A CLOSER LOOK AT ALEMTUZUMAB: Positioning as The New Standard of Care Alemtuzumab First Treatment naïve patients with active disease Drug Classes Therapeutic Effectiveness Sponsor Positioning Competitor Stance Alemtuzumab Tysabri FTY-720 Cladribine ABCRs New benchmark Better efficacy Better effic
Slide 18: A Closer Look at Alemtuzumab: Market Research Suggests Strong Potential Uptake
N=607 A CLOSER LOOK AT ALEMTUZUMAB: Market Research Suggest Strong Potential Uptake Source: PeopleMetrics Rx 2009 Conjoint Study *Cowen & Company report, October 2009 % of Patients High potential product in +$13B MS market by 2012* 2
Slide 19: Shareholder Value Creation Action Plan
Shareholder Value Creation Action Plan Capitalize on Near-term Opportunities 2 Balance Growth with CFROI 3 Improve Operating Margins 4 5 Myozyme, Synvisc-One, and Mozobil are early in launch Alemtuzumab, Mipomersen, and Eliglustat approvals by YE:13E Optimize business mix: disposition of non-core bu
Slide 20: Significant Value Creation Opportunities
Significant Value Creation Opportunities How Do We Analyze Our Business? Assessment based on growth and return benchmarks, including cash flow return on investment (CFROI) 3 Review Assess Shareholder feedback External analysis Board and management continuously review business performance and capital
Slide 21: Components of Value Creation
20 Components of Value Creation Seek Strong Earnings Growth while Maintaining Solid Return on Investment Maintain high return on invested capital Enforce strong financial criteria (focused revenue growth, improving margins and asset productivity) Invest only in the areas defined by our Core Business
Slide 22: Genzyme's Key Criteria for Business Evaluation
21 Genzyme’s Key Criteria for Business Evaluation Commitment to the patient 1 Unmet medical need 2 Best in class, breakthrough therapies 3 Unique value to Genzyme and patients 4 Sustainable rates of growth with high financial returns 5 3
Slide 23: CFROI Economic Profitability
22 CFROI Economic Profitability Incorporates asset life, adjusts asset base for inflation, includes off balance sheet items, excludes non-cash and special items. Corporate Performance Measurement From Revenue Growth to CFROI ROE & ROA Profitability - net income return as a % of equity, assets but th
Slide 24: Genzyme Segment Return Profile 2006
23 Note: Size of bubble represents 2006 revenues. Revenue growth based on 2004-2006 revenue CAGR. Other Renal Hem. Onc. Biosurgery PGH WACC Genzyme Segment Return Profile 2006 3 0% 10% 20% 30% 40% 50% 0% 10% 20% 30% 40% Revenue Growth (%) CFROI (%)
Slide 25: Genzyme Segment Return Profile from 2006 to 2010E
24 Note: Size of bubble represents 2006 and 2010 estimated revenues. Revenue growth based on 2004-2006 revenue CAGR and 2008-2010 estimated revenue CAGR. Other Renal Biosurgery PGH Hem. Onc. WACC Genzyme Segment Return Profile from 2006 to 2010E 3 (25%) (13%) 0% 13% 25% 38% 50% 63% 75% 0% 10% 20% 30
Slide 26: Genzyme Segment Return Profile from 2006 to 2015E
25 Note: Size of bubble represents 2006 and 2015 estimated revenues. Revenue growth based on 2004-2006 revenue CAGR and 2013 estimated -2015 estimated revenue CAGR. Genzyme Segment Return Profile from 2006 to 2015E WACC Other Renal Biosurgery Hem. Onc. PGH MS // 2015E 55% MS Not Risk Adjusted 3 (25%
Slide 27: Seeking Strategic Alternatives for Non-core Assets
Seeking Strategic Alternatives for Non-core Assets Board regularly reviews business portfolio and determined to explore strategic alternatives for three non-core assets: Genetic Testing Revenue: $371 million in 2009 Top 5 provider of reproductive and oncology testing in the US 9 laboratories and ~15
Slide 28: Impact on Genzyme's 2010E Transactions
27 Impact on Genzyme’s 2010E Transactions Pro Forma EPS DILUTIVE EPS ACCRETIVE Reduces CFROI Improves CFROI Note: Size of bubble represents 2010 estimated segment CFROI. Genzyme change in CFROI and accretion / (dilution) assumes sale at mid-point of illustrative segment valuation range. 2010E Pharma
Slide 29: Shareholder Value Creation Action Plan
Shareholder Value Creation Action Plan Capitalize on Near-term Opportunities 2 Balance Growth with CFROI 3 Improve Operating Margins 4 5 Myozyme, Synvisc-One, and Mozobil are early in launch Alemtuzumab, Mipomersen, and Eliglustat approvals by YE:13E Optimize business mix: disposition of non-core bu
Slide 30: Improve Operating Margins and Capital Expenses
29 Improve Operating Margins and Capital Expenses Genzyme has been evaluating its operating margins and expenses as part of its capital allocation review process Continuing oversight and direction by the Board and now by its Capital Allocation Committee Benchmarking against Peer group Outline of a d
Slide 31: Shareholder Value Creation Action Plan
Shareholder Value Creation Action Plan Capitalize on Near-term Opportunities 2 Balance Growth with CFROI 3 Improve Operating Margins 4 5 Myozyme, Synvisc-One, and Mozobil are early in launch Alemtuzumab, Mipomersen, and Eliglustat approvals by YE:13E Optimize business mix: disposition of non-core bu
Slide 32: Genzyme's Capital Structure Discipline
31 Genzyme’s Capital Structure Discipline Cash balance of $962 million in Q1 2010, with undrawn revolver Significant free cash flow generation with over $1 billion of cash flows annually by 2012 Limited current debt outstanding (Debt / 2009 EBITDA of 0.1x) Current S&P credit rating of A-, with signi
Slide 33: Genzyme's New Stock Repurchase Plan
Stock repurchase of $2.0B in two tranches $1.0B near term stock repurchase using debt $1.0B stock repurchase funded by excess cash, cash flows, debt and/or transactions Expected to be implemented over the next 12 months 33 Genzyme’s New Stock Repurchase Plan Note: Size of bubble represents 2010 esti
Slide 34: Genzyme's Value Creation Commitment
34 Genzyme’s Value Creation Commitment Provide transparent and objective: Capital Allocation Balance Sheet Efficiency Segment Operating Performance Transact non core business: Pharmaceutical Genetics Testing Diagnostic Products Continually monitor business and adjust for highest returns Implement $2
Slide 35: Agenda
Agenda Plan for shareholder value creation Genzyme’s board and leadership Icahn’s proxy fight Concluding remarks
Slide 36: Proactively Strengthened Leadership Team
Proactively Strengthened Leadership Team Scott Canute, EVP, President of Global Manufacturing & Corporate Operations Former President of Global Manufacturing at Eli Lilly Ron Branning, SVP, Global Head of Quality Former VP of Quality and Compliance at Gilead Sciences Pamela Williamson, SVP, Global H
Slide 37: Continuing to Enhance Corporate Governance
Continuing to Enhance Corporate Governance Added Board members to enhance financial & manufacturing expertise Robert Bertolini, former CFO of Schering-Plough Ralph Whitworth, Principal, Relational Investors Process underway to add a member with manufacturing expertise Enhanced the role of the Lead I
Slide 38: Genzyme's Board of Directors
Genzyme’s Board of Directors Deep Experience and Expertise in Our Business Henri Termeer, Chairman of the Board (Director since 1983) CEO and President, Genzyme Corporation 37 years experience in the biotechnology and healthcare fields Director of the Pharmaceutical Research and Manufacturers of Ame
Slide 39: Genzyme's Board of Directors: Diversity of Experience
Genzyme’s Board of Directors Diversity of Experience to Address Genzyme’s Dynamic Business ü ü ü ü ü Richard F. Syron, Ph.D. Key Functional Areas of Expertise ü ü ü ü Ralph Whitworth ü ü ü ü ü Victor J. Dzau, M.D. ü ü ü ü ü ü ü Gail K. Boudreaux ü ü ü ü ü Douglas A. Berthiaume ü ü ü Sen. Connie Mack
Slide 40: Commitment to Constructive Engagement with Our Shareholders
Genzyme’s Commitment to Constructive Engagement with Our Shareholders Continuous engagement with shareholders Extensive investor interactions, including calls, analyst days, monthly investor roundtables and one-on-one meetings Independent directors gathered shareholder feedback independent of manage
Slide 41: Continually Improving Governance
Continually Improving Governance to Assure Independent Oversight & Responsiveness to Investors 2003 Established lead director position and enhanced the role in 2010 2006 Abolished staggered Board and fully implemented annual elections of all Directors in 2009 2007 Adopted majority voting 2007 Adopte
Slide 42: Agenda
Agenda Plan for shareholder value creation Genzyme’s board and leadership Icahn’s proxy fight Concluding remarks
Slide 43: Our Assessment of Icahn's Proxy
Our Assessment of Icahn’s Proxy Icahn provided no constructive input or perspective on the company prior to threatening a last minute proxy fight and still has not done so, despite our actively soliciting his views Icahn applies a “one size fits all” approach that is inappropriate for Genzyme’s curr
Slide 44: Icahn's "One Size Fits All" Approach Is Inappropriate for Genzyme
Icahn’s “One Size Fits All” Approach Is Inappropriate for Genzyme Icahn’s stated thesis: All biotechnology companies should be owned by Big Pharma However, this approach has not led to a successful outcome at Biogen Idec Icahn’s attempt to oust the current team could impact Genzyme’s recovery that i
Slide 45: Dissident Slate Lacks Operational Expertise
Dissident Slate Lacks Operational Expertise Name Age Experience Concerns Carl Icahn 74 Founder and Chief Executive Officer, Icahn Enterprises Corporate raider reinvented as a shareholder activist Substantial operational missteps (e.g., TWA, Blockbuster, and Motorola) Lack of industry knowledge Over
Slide 46: Violating Section of the Clayton Act
Violating Section 8 of the Clayton Act Individuals Cannot Simultaneously Serve on Boards of Competitors The two corporations are “engaged in whole or in part in commerce” The two corporations are “by virtue of their business and location of operation, competitors, so that the elimination of competit
Slide 47: Genzyme and Biogen Directly Compete in the Oncology Market
Genzyme and Biogen Directly Compete in the Oncology Market Biogen’s billion dollar product, Rituxan, competes with the following Genzyme products in multiple disease areas: Solid Organ Transplant, Graft vs. Host Disease and Aplastic Anemia Thymoglobulin Acute Lymphoblastic Leukemia Clolar Non-Hodgki
Slide 48: The Election of Dr. Denner or Dr. Mulligan Would Violate the Clayton Act
The Election of Dr. Denner or Dr. Mulligan Would Violate the Clayton Act Dr. Denner and Dr. Mulligan are both directors of Biogen. All three statutory conditions for a violation are met: Genzyme and Biogen are clearly engaged in commerce, Genzyme and Biogen are direct competitors in the oncology mar
Slide 49: Competition Between Genzyme and Biogen Is Expected to Increase Substantially
Competition Between Genzyme and Biogen is Expected to Increase Substantially The two companies will compete head-to-head in the MS space: Biogen is heavily reliant on its MS franchise - Avonex and Tysabri account for a majority of Biogen’s revenues, and Biogen has two additional MS products in clini
Slide 50: Icahn Nominees Have Substantial Financial Interests in Biogen
Mr. Icahn, Dr. Denner, and Dr. Mulligan Have Substantial Financial Interests in Biogen That Put Them at Cross-Purposes with Genzyme Dr. Denner and Dr. Mulligan both own Biogen stock and options. Dr. Denner, as managing director of Icahn Enterprises, LP, also beneficially owns a portion of Mr. Icahn’
Slide 51: Icahn's Biogen Conflicts and Problematic Incentives Are Immediate Concerns
Icahn’s Biogen Conflicts and Problematic Incentives Are Immediate Concerns Genzyme anticipates a launch of alemtuzumab for MS in 2012 and is currently developing its overall launch plan strategy, including proprietary market research, compiling pharmacoeconomic data, planning launch sequencing, and
Slide 52: The Biogen Conflict Prevents Effective Service as Genzyme Directors
The Biogen Conflict Prevents Mr. Icahn, Dr. Denner, and Dr. Mulligan From Serving as Effective Directors of Genzyme The importance of alemtuzumab for MS to Genzyme means that it will be discussed regularly by the board in contexts that are not separate and discrete – for instance, discussions on all
Slide 53: Our Conclusion: Icahn's Nominees Are Tainted By Conflicts of Interest
Our Conclusion: Icahn’s Nominees Are Tainted By Fundamental Conflicts of Interest The election of Dr. Denner or Dr. Mulligan would produce a clear violation of the Clayton Act. Mr. Icahn, Dr. Denner, and Dr. Mulligan have substantial interests in Biogen that fundamentally compromise their ability to
Slide 54: Agenda
Agenda Plan for shareholder value creation Genzyme’s board and leadership Icahn’s proxy fight Concluding remarks
Slide 55: Conclusion: Positioned for Renewed Value Creation
CONCLUSION Positioned for Renewed Value Creation Genzyme’s Board and management team are executing a proven strategy and are on track to restore Genzyme to profitable growth Executing With new directors and new world-class leaders at the operating level, the company is gaining momentum and building
Slide 56: Appendix A – Genzyme's Directors
Appendix A – Genzyme’s Directors
Slide 57: Independent Director Biographies
Independent Director Biographies 6 (current) Chairman Health care Children’s Hospital Trust Board (Boston) 14 (current) Chairman Life Science-Instruments Waters CEO CEO Latest Position Life Science-Instruments Life Science-Instruments Industry Board Experience Waters Chromatography Division of Milli
Slide 58: Independent Director Biographies
Independent Director Biographies 3 President Health Insurance Blue Cross Blue Shield of Illinois 2 (current) Executive VP, President Health Insurance UnitedHealth Group, UnitedHealthcare 3 Executive VP Health Insurance HCSC 1 (current) Director Health Insurance America’s Health Insurance Plans (curr
Slide 59: Independent Director Biographies
Independent Director Biographies 2 (current) Director Biotech Polypore International 3 (current) Director Renewable Energy LS9 29 (current) Principal Consulting BioInformation Associates <1 (current) Director Biotech Green Light, Inc. 8 (current) Director Biotech Biocon Limited Professor & Faculty D
Slide 60: Independent Director Biographies
Independent Director Biographies 4 Senior Advisor Public Policy King & Spalding 18 Senator Government US Congress 4 Senior Advisor Public Policy Shaw Pittman LLP 3 (current) Director Financial American Momentum Bank 9 (current) Director Diagnostics EXACT Sciences 9 (current) Chairman Non-profit H. L
Slide 61: Independent Director Biographies
Independent Director Biographies 3 Director Power-Generation United Thermal 3 Director Communications Technology Tektronix 6 Chairman Business Services Waste Management 8 President Advocacy United Shareholders Association 3 President of Development Power-Generation United Thermal 1 Director Telecom
Slide 62: Board Committee Assignments
Board Committee Assignments Board Member Audit Compensation Nominating / Governance Risk Management Strategic Planning & Capital Allocation Douglas A. Berthiaume Robert J. Bertolini Chair Gail K. Boudreaux Chair Robert J. Carpenter Charles L. Cooney, Ph.D. Chair Victor J. Dzau, M.D. Senator Connie M